Orlando, FL -- (SBWIRE) -- 10/04/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Sarepta Therapeutics Inc (NASDAQ:SRPT), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN).
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares gained 5.52% to $50.68. SRPT’s Director M Kathleen Behrens purchased 6,500 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $37.04 per share, for a total transaction of $240,760.00. Following the completion of the transaction, the director now directly owns 44,166 shares in the company.
Additionally, Deutsche Bank upgraded shares of Sarepta Therapeutic from a hold rating to a buy rating in a report released on Sept. 24. Deutsche Bank currently has $71.00 price objective on the stock, up from their previous price objective of $45.00.
Are investors worried about the recent updates with SRPT? Find out with a free trend analysis HERE
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares gained 5.21% to $0.505. The company on Sept. 30 announced the on-line publication of preclinical results for RX-3117 in a peer reviewed medical journal, Investigational New Drugs, in an article titled, "Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)". Investigational New Drugs is an interdisciplinary journal presenting the latest investigations and discussions of critical questions appropriate to the entire field of new anticancer drug development.
Is RNN going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)